respiratori
bovin
coronavirus
rbcv
emerg
infecti
agent
frequent
isol
respiratori
tract
sampl
cattl
acut
respiratori
tract
diseas
infectivityneutr
hemagglutinininhibit
hai
antibodi
induc
rbcv
infect
monitor
sequenti
serum
sampl
collect
cattl
natur
evolv
experiment
monitor
epizoot
ship
fever
pneumonia
sfp
cattl
nasal
shed
rbcv
begin
epizoot
start
low
level
serum
hai
antibodi
increas
serum
antibodi
day
led
reduct
viru
shed
nasal
secret
major
cattl
day
substanti
rise
serum
hai
antibodi
observ
initi
phase
among
sick
clinic
normal
cattl
infect
rbcv
rbcv
isolationposit
cattl
develop
fatal
sfp
minim
serum
hai
antibodi
cours
diseas
develop
cattl
remain
neg
rbcv
isol
test
enter
epizoot
high
level
serum
hai
antibodi
dramat
increas
next
two
week
protect
sfp
appar
associ
significantli
higher
level
serum
antibodi
begin
epizoot
rbcvneutral
activ
associ
serum
immunoglobulin
g
igg
particularli
subclass
rbcvspecif
hai
antibodi
relat
serum
igg
igm
fraction
numer
wildtyp
coronaviru
strain
recent
isol
nasal
swab
sampl
lung
tissu
cattl
sign
acut
respiratori
tract
distress
includ
sever
form
ship
fever
pneumonia
sfp
viru
isol
multipli
g
clone
human
rectal
cell
georgia
bovin
kidney
bovin
turbin
cell
permiss
previous
describ
respiratori
virus
cattl
identifi
respiratori
bovin
coronavirus
rbcv
role
coronavirus
bovin
enteropathogen
first
recogn
isol
diarrheic
sampl
neonat
calv
sever
gastroenter
coronavirus
also
implic
winter
dysenteri
adult
cattl
princip
dairi
cattl
occasion
pneumoenter
young
calv
coronavirus
refer
enteropathogen
bovin
coronavirus
ebcv
follow
phenotyp
genotyp
properti
differenti
rbcv
ebcv
rbcv
isol
first
g
clone
cell
passag
without
use
trypsin
enhanc
trypsin
activ
requir
isol
wildtyp
ebcv
ii
rbcv
high
cellfus
activ
g
clone
cell
neutral
ph
rang
iii
rbcv
agglutin
mous
rat
chicken
red
blood
cell
rbc
prototyp
ebcv
agglutin
rodent
chicken
rbc
iv
rbcv
high
acetylesteras
ae
activ
wherea
ae
function
ebcv
much
activ
v
compar
analysi
wildtyp
rbcv
ebcv
genom
region
kb
reveal
rbcvspecif
nucleotid
amino
acid
chang
disproport
concentr
within
hemagglutininesteras
gene
spike
gene
genom
region
envelop
e
gene
bovin
coronavirus
bcv
belong
coronavirida
famili
order
nidoviral
larg
envelop
positivestrand
rna
virus
genom
kb
viral
rna
genom
associ
nucleocapsid
phosphoprotein
n
form
helic
nucleocapsid
four
structur
protein
part
lipoprotein
envelop
membran
glycoprotein
ii
glycoprotein
iii
glycoprotein
iv
recent
identifi
e
protein
specif
monoclon
antibodi
mab
ebcv
glycoprotein
inhibit
viru
infect
indic
glycoprotein
elicit
neutral
antibodi
ebcv
infect
acid
identifi
receptor
determin
bind
initi
infect
agglutin
rodent
erythrocyt
glycoprotein
consid
major
viral
structur
protein
bind
neuramin
acidcontain
receptor
bind
glycoprotein
determin
residu
cell
surfac
suggest
function
prereceptor
interact
ebcv
ebcv
also
receptordestroy
enzym
rde
function
mediat
ae
potenti
elut
adsorb
virion
mab
differenti
function
hemagglutinin
ha
rde
activ
rel
low
activ
inhibit
ha
high
titer
activ
inhibit
rde
antibodi
ebcv
infect
cattl
analyz
bovin
sera
immunodiffus
immunoblot
enzymelink
immunosorb
assay
recent
studi
sequenti
humor
immun
respons
rbcv
infect
cattl
suggest
antibodi
glycoprotein
play
signific
role
clear
infecti
viru
induc
protect
viru
infect
purpos
investig
assess
kinet
infectivityneutr
hainhibit
hai
antibodi
rbcv
sera
immunolog
matur
cattl
natur
evolv
epizoot
sfp
defin
correl
hai
activ
previous
report
immunoisotyp
respons
relat
find
isol
rbcv
respiratori
tract
diseas
develop
clearanc
viru
recoveri
phase
experiment
design
report
cattl
includ
epizoot
occur
subject
nasal
blood
sampl
test
time
assembl
orderbuy
barn
day
transport
day
weekli
throughout
pathogenesi
sfp
day
nasal
swab
sampl
taken
virolog
bacteriolog
studi
blood
sampl
serum
harvest
collect
immunolog
investig
cattl
classifi
five
respons
group
base
clinic
sign
respiratori
tract
diseas
result
rbcv
isol
respons
group
includ
cattl
exhibit
clinic
sign
respiratori
tract
diseas
nasal
shed
rbcv
day
day
seven
cattl
shed
rbcv
day
randomli
chosen
respons
group
test
studi
respons
group
contain
five
test
cattl
secret
rbcv
nasal
discharg
without
advers
respiratori
sign
ten
cattl
respons
group
develop
sever
pneumonia
die
day
nine
nasal
shed
rbcv
select
eighteen
cattl
remain
rbcv
isol
neg
eleven
includ
respons
group
fever
respiratori
sign
remain
seven
calv
respons
group
remain
clinic
healthi
investig
sampl
seven
repres
cattl
respons
group
serolog
analyz
sequenti
serum
sampl
select
cattl
analyz
hai
antibodi
cell
line
viru
isol
viru
purif
g
clone
cell
use
passag
level
rbcv
propag
wildtyp
strain
use
second
passag
antigen
prepar
initi
isol
lung
tissu
calf
die
day
stock
prepar
partial
purif
perform
accord
method
zhang
et
al
infect
neutral
assay
serum
sampl
dilut
dulbecco
modifi
minim
essenti
medium
sigma
chemic
co
st
loui
mo
g
glucos
per
liter
buffer
mm
nahco
supplement
penicillin
uml
streptomycin
gml
sigma
chemic
co
heat
inactiv
min
prepar
quadrupl
serial
twofold
dilut
lwell
flatbottom
cell
cultur
plate
costar
corn
ny
serum
antibodi
titer
bcvantibodi
free
serum
normal
calf
titer
includ
posit
neg
control
respect
stock
dilut
dulbecco
modifi
minim
essenti
medium
cell
cultur
infect
dose
ad
lwell
serumviru
mixtur
react
min
l
g
clone
cell
suspens
contain
cell
drop
well
plate
incub
co
incub
examin
daili
invert
microscop
rbcvcharacterist
cytopath
chang
extens
cell
fusion
day
titer
serum
express
reciproc
serum
dilut
complet
inhibit
cytopath
chang
quadrupl
assay
ha
rde
assay
ha
rde
perform
report
wash
rat
rbc
prepar
suspens
phosphatebuff
salin
ph
contain
bovin
serum
albumin
test
hai
serum
sampl
dilut
phosphatebuff
salin
ph
contain
bovin
serum
albumin
heat
inactiv
min
prepar
serial
twofold
dilut
aliquot
vbottom
microtit
plate
costar
cambridg
mass
serum
hai
antibodi
titer
includ
posit
control
bcv
antibodyfre
serum
normal
calf
hai
antibodi
titer
use
neg
control
partial
purifi
stock
dilut
contain
u
ha
rde
use
antigen
fifti
microlit
antigen
ad
serum
dilut
serumantigen
mixtur
react
min
volvol
rat
rbc
suspens
ad
volum
l
plate
shaken
dispers
rbc
suspens
incub
h
serum
hai
antibodi
titer
express
reciproc
highest
dilut
serum
sampl
complet
inhibit
aggreg
rat
rbc
data
analysi
statist
method
serum
hai
antibodi
titer
transform
base
logarithm
statist
analysi
data
present
mean
standard
error
mean
sem
hai
activ
respons
group
compar
analysi
varianc
repeat
measur
design
splitplot
arrang
treatment
pairwis
comparison
treatment
day
differ
conduct
scheff
test
interact
effect
examin
pairwis
test
leastsquar
mean
preplan
comparison
treatment
specif
day
test
consid
signific
probabl
p
total
serum
sampl
collect
test
cattl
analyz
antibodi
hai
antibodi
immunoisotyp
level
hai
activ
pair
hai
antibodi
antibodi
immunoisotyp
level
serum
sampl
serum
sampl
ident
hai
antibodi
level
transform
base
logarithm
group
togeth
well
serum
sampl
nine
specif
hai
antibodi
level
respect
evalu
sensit
specif
hai
antibodi
assay
group
hai
antibodi
antibodi
immunoisotyp
level
compar
specif
hai
activ
linear
regress
analysi
sa
system
present
mean
sem
p
valu
consid
statist
signific
isol
result
rbcv
overt
sign
respiratori
tract
diseas
divid
cattl
experiment
assess
epizoot
sfp
five
respons
group
overal
kinet
serum
hai
antibodi
level
seven
sick
cattl
respons
group
five
clinic
normal
cattl
respons
group
show
signific
differ
fig
b
f
g
level
serum
hai
antibodi
rbcv
initi
low
cattl
respons
group
cattl
respons
group
respect
signific
increas
level
antibodi
serum
observ
cattl
day
reach
p
p
day
cattl
respons
group
remain
high
fig
b
increas
level
serum
hai
antibodi
statist
signific
cattl
respons
group
day
p
substanti
rise
level
serum
hai
antibodi
detect
cattl
respons
group
experi
p
fig
g
nine
rbcv
isolationposit
cattl
respons
group
develop
fatal
sfp
low
hai
level
day
respect
fig
h
increas
serum
antibodi
level
detect
hai
antibodi
level
rose
minim
cours
diseas
develop
signific
differ
observ
kinet
serum
hai
antibodi
level
respons
group
fig
e
j
remark
higher
respons
group
fig
b
f
g
level
antibodi
serum
significantli
increas
first
week
reach
p
p
day
cattl
respons
group
respect
remain
high
level
fig
e
serum
antibodi
level
cattl
respons
group
day
day
significantli
higher
cattl
respons
group
day
p
day
p
level
hai
antibodi
serum
initi
dramat
increas
p
p
day
cattl
respons
group
respect
remain
high
fig
j
comparison
serum
activ
hai
level
shown
fig
e
correl
serum
activ
correspond
hai
level
especi
signific
p
excel
coeffici
determin
r
level
versu
hai
level
fig
hai
level
versu
level
fig
correl
serum
activ
igm
level
present
fig
c
respect
best
correl
exist
level
p
valu
r
fig
correl
serum
activ
level
slightli
lower
r
result
still
excel
agreement
especi
signific
p
fig
correl
activ
igm
level
lowest
r
remark
p
fig
serum
hai
activ
also
compar
igm
level
fig
g
h
serum
level
highli
correl
serum
hai
activ
r
valu
p
valu
respect
fig
h
correl
igm
serum
hai
activ
much
higher
r
signific
p
serum
activ
fig
f
kinet
serum
hai
activ
rbcv
defin
first
time
natur
evolv
experiment
assess
epizoot
sfp
correl
viru
clearanc
respiratori
tract
character
function
effector
mechan
bovin
humor
immun
respons
possibl
enzymelink
immunosorb
assay
immunodiffus
test
immunoblot
assay
similar
investig
young
calv
ebcv
infect
report
except
vivo
studi
inocul
attenu
virul
ebcv
surgic
isol
thirtyvella
intestin
loop
colostrumdepriv
calv
serum
antibodi
present
day
postinocul
igm
iga
viru
detect
intestin
loop
fluid
day
postinocul
strong
primari
antibodi
respons
detect
among
cattl
nasal
shed
rbcv
earli
stage
epizoot
serum
antibodi
level
initi
low
significantli
increas
day
simultan
declin
nasal
rbcv
shed
cattl
within
week
intranas
vaccin
calv
modifi
live
viru
infecti
bovin
rhinotrach
induc
neutral
activ
serum
day
find
along
previou
studi
antigen
rbcv
structur
protein
immunoblot
assay
highlight
import
glycoprotein
induct
antibodi
rbcv
infect
similar
report
ebcv
human
respiratori
coronaviru
infect
serum
hai
activ
higher
serum
first
week
investig
previou
observ
antigen
rbcv
structur
protein
rbcv
infect
indic
viral
antigen
recogn
initi
stage
bovin
immun
respons
rbcv
infect
glycoprotein
induc
antibodi
week
earlier
glycoprotein
wherea
glycoprotein
induc
persist
antibodi
respons
structur
favor
expos
epitop
abund
glycoprotein
might
facilit
earli
strong
hai
antibodi
respons
interestingli
remark
rise
level
serum
hai
activ
observ
among
sick
among
clinic
normal
cattl
day
immunolog
injuri
mediat
larg
antibodi
glycoprotein
play
import
role
pathogenesi
felin
infecti
periton
fip
immun
complex
format
complement
deposit
incit
pyogranulomat
lesion
fip
mab
glycoprotein
fip
viru
enhanc
infect
macrophag
vitro
furthermor
purifi
glycoprotein
ebcv
document
exhibit
higher
ha
activ
rodent
rbc
purifi
glycoprotein
therefor
propos
rapid
increas
level
hai
antibodi
primarili
glycoprotein
could
result
deposit
antibodyantigen
complex
complement
aggrav
rbcv
infect
possibl
patholog
mechan
earli
diseas
enhanc
infect
neutral
hai
antibodi
could
detect
minim
level
serum
cattl
fatal
sfp
high
titer
rbcv
reach
pfug
detect
pneumon
lung
tissu
cattl
inabl
develop
neutral
antibodi
glycoprotein
could
result
sever
rbcv
infect
lung
evid
favor
pasteurella
haemolytica
infect
typic
sfp
interact
infect
lung
rbcv
p
haemolytica
sfp
requir
addit
studi
high
level
hai
antibodi
rbcv
infect
serum
develop
initi
increas
subgroup
cattl
remain
complet
rbcv
isol
neg
investig
importantli
major
differ
cattl
without
sign
respiratori
tract
diseas
serum
antibodi
level
first
week
clinic
normal
cattl
significantli
higher
level
cattl
develop
clinic
sign
suggest
high
level
antibodi
rbcv
enabl
cattl
resist
rbcv
infect
effici
thu
prevent
clinic
sign
sfp
high
correl
serum
hai
activ
document
howev
result
correl
serum
hai
activ
immunoisotyp
level
along
detail
illustr
fig
suggest
igg
especi
might
contain
major
rbcvspecif
activ
bovin
serum
wherea
igg
igm
might
play
import
role
serum
hai
activ
result
impli
detect
serum
rbcvspecif
hai
antibodi
use
earli
stage
rbcv
infect
wherea
monitor
serum
rbcvspecif
activ
may
better
indic
overal
outcom
diseas
develop
result
indic
measur
rbcvspecif
igg
particularli
may
provid
good
estim
protect
antibodi
level
